Surgery's purpose is not cure, but to delay drug resistance
At National Taiwan University Hospital, a small but carefully designed trial has begun to reframe what surgery can mean for patients whose lung cancer has already spread — not as a cure, but as a strategic act of delay. By removing the primary tumor after an initial course of targeted drug therapy, researchers found that the risk of disease progression fell by more than half compared to medication alone. The work suggests that even in advanced illness, the body's geography still matters, and that local intervention can extend the window before cancer learns to resist the tools we use against it.
- A 52% reduction in progression risk challenges the long-held assumption that surgery has no meaningful role once lung cancer has spread beyond its origin.
- The trial's design — drug therapy first, then surgery for half the patients — created a controlled collision between systemic and local treatment strategies in 91 patients with EGFR-mutated metastatic disease.
- Molecular analysis of resected tumors uncovered TP53 mutations in 37% of cases and revealed that different EGFR subtypes respond differently, adding urgency to the question of which patients should be selected for surgery.
- Two patients showed complete pathologic response — no viable cancer cells remaining — raising the possibility that for some, the combined approach approaches something closer to remission.
- Researchers are careful to frame the goal as delay, not cure: surgery appears to push back the moment drug resistance emerges, buying time and biological intelligence rather than promising an endpoint.
Researchers at National Taiwan University Hospital have produced early evidence that removing a primary lung tumor after initial drug treatment may meaningfully slow the progression of cancer that has already spread. The trial enrolled 91 patients with metastatic non-small cell lung cancer carrying EGFR mutations — genetic alterations that make tumors responsive to a class of drugs called tyrosine kinase inhibitors.
Patients first received 12 weeks of afatinib to shrink their tumors and gauge drug response. Half then continued on medication alone, while the other half underwent surgery to remove the primary chest tumor, with radiation available for distant metastases. The researchers were explicit about their intent: not to cure, but to eliminate residual disease and delay the emergence of drug resistance.
The results showed a hazard ratio of 0.48 — a statistically significant 52% reduction in progression risk for the surgical group. Among those who underwent resection, roughly 29% showed major pathologic response, and two patients had no viable cancer cells remaining in their surgical specimens.
Molecular sequencing of resected tissue from 30 patients found TP53 mutations in 37% of cases and co-mutations in half. While these findings did not yet correlate with survival differences, they offered a foundation for understanding which patients might benefit most. Notably, patients with Exon 19 deletions showed higher rates of pathologic response to the drug, while those with L858R mutations appeared to gain more from the surgery itself.
Presenting at the IASLC 2025 World Conference, Dr. Pei-Hsing Chen emphasized that the trial's value lay not only in survival numbers but in the tissue access it created — a window into how tumors evolve under drug pressure. The broader implication is a quiet but significant shift: in advanced lung cancer, carefully timed local interventions may extend the period before resistance takes hold, turning surgery into a tool for buying time and gathering knowledge rather than seeking a final answer.
Researchers at National Taiwan University Hospital have found early evidence that removing a patient's primary lung tumor after initial drug treatment may slow the progression of advanced cancer that has already spread to other parts of the body. The discovery comes from a randomized trial of 91 patients with metastatic non-small cell lung cancer driven by EGFR mutations—a genetic alteration that makes tumors responsive to a class of drugs called tyrosine kinase inhibitors.
The study design was straightforward but novel. Patients first received 12 weeks of afatinib, an EGFR inhibitor, to shrink their tumors and assess how well the drug was working. Then half the group continued taking the medication alone, while the other half underwent surgery to remove the primary tumor in the chest, with the option of radiation therapy for distant metastases. The surgical team aimed for complete removal with negative margins—the standard oncologic goal—but the researchers were clear about what they were not trying to do: cure the disease. Instead, they framed surgery as a tactical move within a broader treatment strategy, a way to eliminate residual disease and potentially delay the moment when cancer cells develop resistance to the drug.
The early results showed a meaningful difference between the two approaches. Patients who had surgery experienced a 52 percent reduction in the risk of disease progression compared to those who continued on medication alone. The hazard ratio—a statistical measure of how much the surgery group benefited—was 0.48, a finding that reached statistical significance. Among the 34 patients who underwent resection, about 29 percent showed a major pathologic response, meaning the tumor had been largely destroyed by the prior drug therapy. Two patients achieved a complete pathologic response, with no viable cancer cells remaining in the surgical specimen.
The molecular analysis of resected tissue revealed patterns that may help guide future treatment decisions. Researchers performed next-generation sequencing on tissue from 30 patients and found TP53 mutations—alterations in a gene that normally acts as a brake on cancer growth—in about 37 percent of cases. Half the patients carried additional co-mutations alongside their EGFR alteration. These molecular findings did not yet correlate with survival differences in this early analysis, but they provide a foundation for understanding which patients might benefit most from the combined approach.
One genetic subgroup showed particular interest: patients with Exon 19 deletions in their EGFR gene had higher rates of major pathologic response to the initial drug therapy, suggesting their tumors were especially sensitive to the inhibitor. By contrast, patients with the L858R mutation—a different type of EGFR alteration—showed a lower hazard ratio for progression, meaning they seemed to benefit more from the surgical intervention itself.
Dr. Pei-Hsing Chen, who presented the findings at the International Association for the Study of Lung Cancer's 2025 World Conference, emphasized that the trial's value extended beyond the survival numbers. The surgical approach provided access to tumor tissue at a moment when it had been exposed to targeted therapy, creating an opportunity to understand how cancers respond and evolve under drug pressure. This tissue-based intelligence could inform which patients are most likely to benefit from surgery in future trials and help oncologists refine their selection criteria.
The work represents a shift in how researchers think about advanced lung cancer. Rather than viewing metastatic disease as uniformly incurable and focusing solely on extending life with systemic drugs, this trial suggests that carefully timed local interventions—surgery, radiation—might extend the window before drug resistance takes hold. The goal is not to cure, but to buy time and gather information. For patients with EGFR-mutated lung cancer that has spread, that distinction could matter considerably.
Citas Notables
The purpose of surgery is not curative, but rather to serve as part of a combination therapy to prolong the interval before drug resistance develops.— Dr. Pei-Hsing Chen, National Taiwan University Hospital
La Conversación del Hearth Otra perspectiva de la historia
Why does removing a tumor that's already spread make sense? Isn't the cancer already everywhere?
That's the right instinct, but the thinking here is different. The primary tumor in the lung is often the source of new mutations and resistance. By removing it after the drug has done its initial work, you're eliminating a reservoir of cells that might otherwise develop resistance to the inhibitor.
So surgery isn't meant to cure anyone?
No. The researchers were explicit about that. They see surgery as part of a combination strategy—a way to delay the inevitable moment when cancer cells mutate and stop responding to the drug. It's about extending the progression-free interval, not achieving cure.
What surprised you most in the data?
The tissue analysis. They got to look at tumors that had been exposed to the drug for 12 weeks, and they found TP53 mutations in more than a third of cases. That kind of molecular snapshot doesn't happen in most trials. It gives you real insight into how these cancers are evolving.
Did everyone benefit equally from surgery?
Not quite. Patients with Exon 19 deletions responded better to the drug alone, while those with L858R mutations seemed to benefit more from having surgery added. That suggests future trials might use genetic subtype to decide who gets surgery and who doesn't.
What happens next?
This is Phase II data—early, but promising enough to justify larger trials. The real question is whether this approach actually extends overall survival, not just delays progression. And whether the tissue insights can help oncologists predict who will respond best.